Almac Group boosts U.S. footprint with new jobs, investment

Ireland and U.S.-based CDMO Almac will inject $5.2 million into its U.S. ops and created around 80 new jobs in research heartland North Carolina as part of its “celebration” of its 20 years in North America.

“This latest investment and increase in capacity at our Durham facility is a sign of our continuing commitment to offer market driven solutions to our client base,” says Donna Christopher, global VP of operations at Almac Clinical Services, in a statement.

“We are delighted to mark our 20th year in the US with such a significant announcement--once again reinforcing our dedication to global expansion.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The money will go toward the boosting its Clinical Services facility, as well as its Diagnostics and Clinical Technologies operations in the CRO-laden state.

Robert Dunlop, president and MD at Almac Clinical Services, added: “We are delighted to announce further investment in our Durham facilities enabling us to continue to support our clients’ needs and meet the increased demands for our integrated services and I look forward to our continuing success over the next twenty years and beyond.”


Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.